Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura

Investigational Site Number : 0400001, Vienna

Investigational Site Number : 0560003, Yvoir

Investigational Site Number : 2760006, Berlin

Investigational Site Number : 3800006, Genova

Investigational Site Number : 3800001, Milan

Johns Hopkins University- Site Number : 8400007, Baltimore

Investigational Site Number : 7240001, Madrid / Madrid

Investigational Site Number : 2760004, Hanover

University of Alabama- Site Number : 8400011, Birmingham

Investigational Site Number : 3800004, Vicenza

Investigational Site Number : 3800005, Verona

The Ohio State University Comprehensive Cancer Center - Site Number : 8400001, Columbus

Investigational Site Number : 2760003, Essen

Investigational Site Number : 2030002, Hradec Králové

Investigational Site Number : 2760002, Cologne

Investigational Site Number : 2500005, Lille

Investigational Site Number : 2760001, Frankfurt am Main

Investigational Site Number : 2030001, Brno

Investigational Site Number : 2500003, Paris

Investigational Site Number : 2500001, Paris

Investigational Site Number : 2500002, Bois-Guillaume

Investigational Site Number : 3800003, Avellino

University of Utah- Site Number : 8400009, Salt Lake City

Duke University Medical Center Site Number : 8400022, Durham

Investigational Site Number : 1240001, Toronto

Investigational Site Number : 2030003, Prague

Investigational Site Number : 2760007, Leipzig

Investigational Site Number : 3920003, Kurashiki-shi

Investigational Site Number : 3920001, Iruma-gun

Investigational Site Number : 5280002, Amersfoort

Investigational Site Number : 8260001, London

Investigational Site Number : 8260002, Liverpool